Achilles Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Selling, General & Admin	15.97	17.01	21.12	21.97	11.1	4.7
Research & Development	55.96	58.15	50.06	42.12	22.63	9.07
Operating Expenses	71.93	75.16	71.18	64.1	33.73	13.78
Operating Income	-71.93	-75.16	-71.18	-64.1	-33.73	-13.78
Currency Exchange Gain (Loss)	-1	-1	3.8	2.5	0.1	-0.4
Other Non Operating Income (Expenses)	6.64	7.08	3.52	0.63	0.43	0.19
EBT Excluding Unusual Items	-66.29	-69.07	-63.87	-60.96	-33.2	-13.99
Asset Writedown	-0.1	-0.1	-7.2	-0.1	-	-
Pretax Income	-66.39	-69.17	-71.07	-61.06	-33.2	-13.99
Income Tax Expense	0.49	0.49	0.11	0.04	0	-
Net Income	-66.88	-69.67	-71.18	-61.1	-33.2	-13.99
Net Income to Common	-66.88	-69.67	-71.18	-61.1	-33.2	-13.99
Shares Outstanding (Basic)	40	40	39	29	1	1
Shares Outstanding (Diluted)	40	40	39	29	1	1
Shares Change (YoY)	1.45%	2.13%	36.59%	2587.54%	66.03%	18.35%
EPS (Basic)	-1.66	-1.74	-1.82	-2.13	-31.14	-21.79
EPS (Diluted)	-1.66	-1.74	-1.82	-2.13	-31.14	-21.79
Free Cash Flow	-64.07	-49.55	-67.05	-66.92	-37.1	-15.08
Free Cash Flow Per Share	-1.59	-1.24	-1.71	-2.33	-34.80	-23.49
EBITDA	-67.23	-70.44	-67.49	-60.81	-32.96	-13.47
D&A For EBITDA	4.7	4.71	3.69	3.29	0.77	0.3
EBIT	-71.93	-75.16	-71.18	-64.1	-33.73	-13.78

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q